Bioresponsive Hyaluronic Acid-Based Hydrogel Inhibits Matrix Metalloproteinase-2 in Glioblastoma Microenvironment

Area of Science:

• Biomaterials Science
• Oncology
• Drug Delivery

Background:

• Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with poor prognosis.
• Complete surgical resection of GBM is often limited by tumor invasiveness and anatomical constraints.
• Matrix metalloproteinases (MMPs) play a crucial role in GBM progression and invasion.

Purpose of the Study:

• To develop and characterize a novel bioresponsive hydrogel for glioblastoma surgery.
• To evaluate the hydrogel's suitability for filling surgical cavities and delivering therapeutics.
• To assess the selective inhibition of MMPs by the hydrogel in the GBM microenvironment.

Main Methods:

• Synthesis and characterization of a hyaluronic acid (HA) based hydrogel cross-linked with a branched metalloproteinase inhibitor (MMPI).
• Assessment of the hydrogel's physical properties for surgical cavity filling and in situ drug delivery.
• Evaluation of the hydrogel's bioresponsive behavior and selective MMP inhibition (MMP-2 vs. MMP-9) in a glioblastoma context.

Main Results:

• The developed HA-MMPI hydrogel possesses suitable physical properties for surgical applications.
• The hydrogel demonstrates effective in situ delivery of the MMP inhibitor.
• The material exhibits selective inhibition of MMP-2 over MMP-9 within the glioblastoma microenvironment.

Conclusions:

• The HA-MMPI hydrogel represents a promising bioresponsive material for glioblastoma treatment.
• This approach could enhance surgical outcomes by controlling the tumor microenvironment post-resection.
• Selective MMP inhibition offers a targeted strategy to combat GBM invasiveness.